Latest News

31 July 2014

Appendix 4C - Quarterly Cashflow Statement

Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 June 2014.

Read more

21 July 2014

VivaGel® condom receives TGA device certification - Launch preparations to follow

Starpharma today announced achievement of a major milestone with the receipt of Conformity Assessment Certification for the VivaGel® condom by the Australian Therapeutic Goods Administration (TGA). This TGA certification is similar to CE certification of devices (CE Mark) in Europe.

Read more

14 July 2014

FDA Grants SPA Agreement for Phase 3 Recurrent BV Trial

Starpharma today announced that the US Food and Drug Administration (FDA) has granted Special Protocol Assessment (SPA) agreement on the design and planned analyses of the phase 3 clinical studies of the VivaGel® bacterial vaginosis (BV) product for the prevention of recurrent BV.

Read more

13 June 2014

Rob Thomas succeeds retiring Chairman Peter Bartels

Starpharma today confirmed Mr Peter Bartels AO will retire as Chairman as part of a planned succession. As announced in November 2013, Mr Rob Thomas AM will succeed Mr Bartels as Chairman, effective today.

Read more

In the media

5 June 2014

Starpharma's clinical trial programs accelerating

Starpharma today provided an update on the progress of its clinical trial programs, which include the Phase 1 DEP™ docetaxel trial and the Phase 3 pivotal trials of VivaGel® for prevention of recurrent bacterial vaginosis (BV).


 Phase 1 DEP™ docetaxel trial:

- Ethics approval at 3 sites in Australia

- Enrolling patients; a number having received multiple cycles of therapy

- No evidence of neutropenia

 Phase 3 VivaGel® for prevention of recurrent BV:

- Agreement with EMA and FDA on study design

- First ethics approval obtained

- Quintiles CRO engaged

- Nearing commencement

Read more

10 April 2014

The Business on ABC TV: Interview with Starpharma CEO Jackie Fairley

ABC News’ The Business Presenter Ticky Fullerton interviewed Starpharma CEO Dr Jackie Fairley on Thursday 10 April 2014. With the biotechnology sector predicted to offer some of the best growth, Ticky discussed the newly announced expansion of Starpharma’s drug delivery platform, the receipt of $4.7M of R&D tax incentives and its benefits for the Australian biotechnology industry and more Australian-based clinical trials.

Watch the video (external link)

20 November 2013

Australian Financial Review: Biotech sector revival as appetite for risk grows

Australian Financial Review Journalist, Bina Brown reported on an Australian equities market shift away from resources into biotech and included Starpharma as a company to watch. The article noted the recent positive data showing that the Company’s delivery technology can make commonly use cancer drugs work a lot better as well as reduce side effects that can result in patients having to stop treatment.

 “[Starpharma’s] delivery technology can not only make commonly used cancer drugs work a lot better, but can get rid of the main side-effects that can mean cancer patients have to stop using them.. ‘If the human data is anything like what we have seen in preclinical ­studies, this will be a total game changer.’”

16 October 2013

The Business on ABC TV: Interview with Starpharma CEO Jackie Fairley

ABC News’ The Business Presenter Ticky Fullerton interviewed Starpharma CEO Dr Jackie Fairley on Wednesday 16th October 2013. Ticky discussed the positive results of Starpharma’s dendrimer version of oxaliplatin.


 Watch the video (external link)

Shareholder Updates

12 June 2014

Shareholder Update: June 2014

In this issue:

› VivaGel® BV prevention of recurrence: start of phase 3 trials close

› R&D tax incentive cash received

› DEP™ docetaxel trial progressing well

› VivaGel®-coated condom: preparing for launch

› VivaGel® BV symptomatic relief product: commercial and regulatory progress

› Strong results for dendrimer enhanced agrochemicals


Download: Shareholder Update: June 2014 ( pdf file, 2MB)

17 December 2013

Shareholder Update: December 2013

In this issue:

› Dendrimer-Docetaxel to enter human clinical trials

› VivaGel® Phase 3 trial for prevention of recurrent BV

› VivaGel®-coated condom: Consumer feedback

› Impressive results for Dendrimer-Enhanced Oxaliplatin

› Progress continues in agrochemical activities

› Appointment of Rob Thomas

› SPL TV – a new channel


Download: Shareholder Update: December 2013 ( pdf file, 1MB)

Sign up to receive news here

© Starpharma Holdings Limited 2014